[go: up one dir, main page]

DK1169058T3 - Insulinlignende vækstfaktorbindingsprotein-4-protease - Google Patents

Insulinlignende vækstfaktorbindingsprotein-4-protease

Info

Publication number
DK1169058T3
DK1169058T3 DK00914965T DK00914965T DK1169058T3 DK 1169058 T3 DK1169058 T3 DK 1169058T3 DK 00914965 T DK00914965 T DK 00914965T DK 00914965 T DK00914965 T DK 00914965T DK 1169058 T3 DK1169058 T3 DK 1169058T3
Authority
DK
Denmark
Prior art keywords
protease
insulin
growth factor
binding protein
factor binding
Prior art date
Application number
DK00914965T
Other languages
English (en)
Inventor
Michael Toft Overgaard
Claus Oxvig
Cheryl A Conover
Original Assignee
Mayo Foundation
Michael Toft Overgaard
Claus Oxvig
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation, Michael Toft Overgaard, Claus Oxvig filed Critical Mayo Foundation
Application granted granted Critical
Publication of DK1169058T3 publication Critical patent/DK1169058T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489Metalloendopeptidases (3.4.24)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
DK00914965T 1999-03-15 2000-03-15 Insulinlignende vækstfaktorbindingsprotein-4-protease DK1169058T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12454199P 1999-03-15 1999-03-15
PCT/US2000/006728 WO2000054806A1 (en) 1999-03-15 2000-03-15 Insulin-like growth factor binding protein-4 protease

Publications (1)

Publication Number Publication Date
DK1169058T3 true DK1169058T3 (da) 2007-09-10

Family

ID=22415480

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00914965T DK1169058T3 (da) 1999-03-15 2000-03-15 Insulinlignende vækstfaktorbindingsprotein-4-protease

Country Status (10)

Country Link
US (2) US20060148018A1 (da)
EP (1) EP1169058B1 (da)
JP (1) JP2002538804A (da)
AT (1) ATE361756T1 (da)
AU (3) AU783035B2 (da)
CA (1) CA2367360C (da)
DE (1) DE60034779T2 (da)
DK (1) DK1169058T3 (da)
ES (1) ES2288470T3 (da)
WO (1) WO2000054806A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115382B1 (en) 1999-03-15 2006-10-03 Mayo Foundation For Medical Education And Research Method for detecting IGFBP-4 protease without detecting IGFBP-4 protease/proMBP Complex
CA2818654A1 (en) 2000-10-20 2002-04-25 Como Biotech Aps Pregnancy-associated plasma protein-a2 (papp-a2)
US6436629B1 (en) * 2000-10-27 2002-08-20 The Regents Of The University Of California Modulating angiogenesis
US6500630B2 (en) * 2001-01-12 2002-12-31 Mayo Foundation For Medical Education And Research Marker for inflammatory conditions
EP1709448B1 (en) * 2004-01-28 2008-10-22 Turun Yliopisto Improved method for diagnosing acute coronary syndrome
WO2005087805A1 (en) * 2004-03-05 2005-09-22 Regenerx Biopharmaceuticals, Inc. Treating or preventing extracellular matrix build-up
GB0910751D0 (en) * 2009-06-23 2009-08-05 Procure Therapeutics Ltd Prostate cancer vaccine
FI20095733A0 (fi) 2009-06-29 2009-06-29 Hytest Oy IGFBP-4-fragmenttien määrittäminen diagnostisena menetelmänä
GB201016864D0 (en) * 2010-10-06 2010-11-17 Univ Aston Therapeutic methods
KR102662580B1 (ko) * 2017-07-26 2024-05-03 세키스이 메디칼 가부시키가이샤 변이 유전자 검출 방법
EP4619023A1 (en) 2022-11-15 2025-09-24 Calico Life Sciences LLC Anti-papp-a antibodies and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021686A1 (en) * 1993-03-19 1994-09-29 Northern Sydney Area Health Service Papp-a, its immunodetection and uses
US5876433A (en) * 1996-05-29 1999-03-02 Ethicon, Inc. Stent and method of varying amounts of heparin coated thereon to control treatment
DE19757250A1 (de) * 1997-12-22 1999-07-01 Forssmann Wolf Georg Prof Dr Insulin-like growth factor binding protein und seine Verwendung

Also Published As

Publication number Publication date
DE60034779D1 (de) 2007-06-21
WO2000054806A1 (en) 2000-09-21
US20090191640A1 (en) 2009-07-30
JP2002538804A (ja) 2002-11-19
US20060148018A1 (en) 2006-07-06
DE60034779T2 (de) 2008-01-17
CA2367360C (en) 2011-08-09
EP1169058A4 (en) 2002-07-17
ATE361756T1 (de) 2007-06-15
AU2009200138A1 (en) 2009-02-12
AU2009200138B2 (en) 2012-10-11
AU3627800A (en) 2000-10-04
ES2288470T3 (es) 2008-01-16
AU2005244559A1 (en) 2006-01-19
EP1169058B1 (en) 2007-05-09
EP1169058A1 (en) 2002-01-09
AU2005244559B2 (en) 2008-11-27
AU783035B2 (en) 2005-09-15
CA2367360A1 (en) 2000-09-21

Similar Documents

Publication Publication Date Title
MXPA03011386A (es) Proteina de union para su uso en la regeneracion de hueso o cartilago.
DE60133029D1 (de) Mittel zur prävention oder behandlung von psoriasi
WO1998033509A3 (en) Useful properties of human lactoferrin and variants thereof
NO20005224D0 (no) BTK inhibitorer og fremgangsmÕter for deres identifikasjon og anvendelse
WO2001031580A3 (en) Methods and devices for identifying patterns in biological systems
FR2801189B1 (fr) Implant pour raccourcissement osseux, et en particulier, metatarsien
AU2002365875A1 (en) Stent designed for the delivery of therapeautic substance or other agents
DE69010764D1 (de) Verfahren für chirurgische Implantate.
PT1427409E (pt) Métodos para tratar ou para impedir a inflamação vascular utilizando inibidor(es) de absorção de esteróis
DE60034779D1 (de) Insulinartiger-wachstumsfaktorbindungsprotein-4-protease
ATE273031T1 (de) Aminobiguanide und ihre verwendung zur desinfektion von kontaktlinsen und konservierung von pharmazeutischen zubereitungen
WO2001031579A3 (en) Methods and devices for identifying patterns in biological patterns
SE9802937D0 (sv) Novel compounds
WO2001062784A3 (en) Use of breast cancer associated membrane proteins (bcmp) for treatment, prophylaxis and diagnosis of breast cancer
DK1353948T3 (da) Oplöselige biologiske analoge til bata-amyloidpeptid
DE69943222D1 (de) Menschliche ubiqutin ligase e3. verwendung für die modulation von nf-kappa b
IT1317070B1 (it) Pilastro di guarigione per immobilizzazione intrachirurgica diimpianti dentali per carico immediato.
DK1418905T3 (da) Terapeutisk middel til depletering af en uönsket proteinpopulation fra plasma
GB9930768D0 (en) Composition
GB9811221D0 (en) Bacterial-pheromones and uses therefor
IL139144A0 (en) Mycobacterial inhibitors
MXPA04010915A (es) Base y procedimiento de conocimiento de recursos humanos dinamicos.
IT1290910B1 (it) 2-amminotetralina otticamente attiva, procedimento per la sua preparazione e composizioni farmaceutiche che la contengono, attive
DE60203256D1 (de) System für eine implantierbare medizinische Vorrichtung
AU2002349818A1 (en) Method and device for determining the minimum erythemal dose